NextGen Research Day on June 5th, 2024 in Lucerne
The final selected c4c non-industry Proof of Viability studies includes three studies covering different diseases and age groups.
Paracetamol in Premature Babies
This study will assess the effectiveness of paracetamol on the closure of the ductus arteriosus and the increase in surviving without severe morbidity in extremely premature infants. The study aims to recruit around 800 babies in 17 European countries.
In Switzerland we have study sites in Zurich, Geneva and Lausanne.